Skip to content

New MEMS is the first to capture and classify CTC’s by phenotype.

For most cancer patients, primary tumours are often not the most deadly. Instead, it is the metastatic tumours – tumours that spread from their original location to other parts of the body – that are the cause of most cancer deaths.

The catalysts behind the formation of these deadly metastatic tumours are believed to be cancer cells that are launched into the bloodstream from the original site of the cancer. Researchers are very interested in leveraging these circulating tumour cells, or CTCs, which have the potential to allow the properties of a tumour to be better understood without a biopsy, and may also help physicians recognize how aggressive a tumour is and whether it is likely to cause metastatic disease.

However, not all CTCs in a given patient are alike. Recent discoveries have shown that CTCs are highly heterogeneous, with individual cancer cells possessing very different molecular characteristics, and that only a small subset of these cells actually possess the metastatic potential to spread the disease throughout the body.

Current technologies exist that allow these circulating cells to be captured from the blood of cancer patients, but they are not well equipped to differentiate between the various CTCs present in the blood sample. Instead, they simply count the number of CTCs in a patient sample, rather than identifying the cells that possess the highest metastatic potential. As a result, these tools are less than ideal as they are only able to provide general information on the levels of CTCs rather than a more focused understanding of the disease and its aggressiveness.

Researchers from the University of Toronto have developed a new device that provides a way to visualize the heterogeneity of CTCs, and have published their findings in the journal Angewandte Chemie. Using nanoparticles to tag cells, this device sorts the CTCs collected in a sample into discrete subpopulations based on the phenotype of the cells, and provides a snapshot of the nature of the tumour cells present in patients’ blood.

Recognizing that characterizing the phenotype of circulating tumour cells is more useful for cancer management than quantitating the cells present in a blood sample, the team set out to devise a method that would allow them to capture and distinguish between these cells.  In the lab, the team were able to demonstrate that the tool was not only highly effective at differentiating these cells, but also proved to be more sensitive than the current leading methods of cellular sorting.

Partnering with collaborators at the Sunnybrook Health Sciences Centre and the London Health Sciences Centre, the researchers collected samples from prostate cancer patients to test the efficacy and ability of the diagnostic platform.

Through this study, over 20 patients with localized prostate cancer were tested.  Interestingly, significant levels of these circulating tumour cells were observed in all of the patients. Even more intriguing was the observation of very different subpopulation profiles across this group of patients that all received very similar clinical diagnoses, indicating that molecular­‐level difference may exist in the patients’ tumours.

While this study only involved a small number of patients, further validation is planned with several other cancers, including breast, colon, ovarian, lung, and pancreatic cancer.

Ultimately, the team believe that this sensitive technology possesses the potential to provide more useful information about these cells, leading to better diagnoses and improved patient outcomes.

As a result, the team are excited to pursue new research opportunities in an effort to more accurately and less invasively diagnose and improve the health outcomes for cancer patients.

Source:  University of Toronto Faculty of Applied Science & Engineering

VCaP cells spiked in blood captured in VV chip were used for validation of the chip.  Nanoparticle-Mediated Binning and Profiling of Heterogeneous Circulating Tumor Cell Subpopulations.  Kelley et al 2014.
VCaP cells spiked in blood captured in VV chip were used for validation of the chip. Nanoparticle-Mediated Binning and Profiling of Heterogeneous
Circulating Tumor Cell Subpopulations. Kelley et al 2014.

Healthinnovations View All

Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.

Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.

Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.

Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.

Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.

An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.

One thought on “New MEMS is the first to capture and classify CTC’s by phenotype. Leave a comment

  1. Pingback: New MEMS is the first to capture and classify C...

Leave a Reply

Translate »